ANOS1: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
imported>ProteinBoxBot
(←Created page with '{{Infobox_gene}} '''Anosmin 1''' is a protein that in humans is encoded by the ANOS1 gene. <ref name="entrez"> {{cite web | title = Entrez Gene: Anosmin...')
 
imported>Veryproicelandic
(added some links, removed that flag, cleaned up the syntax...)
 
Line 1: Line 1:
{{Orphan|date=January 2019}}
{{Infobox_gene}}
{{Infobox_gene}}


'''Anosmin 1''' is a [[protein]] that in humans is encoded by the ANOS1 [[gene]].
'''Anosmin 1''' is a [[protein]] that in [[human]]s is encoded by the ANOS1 [[gene]].
<ref name="entrez">
<ref name="entrez">
{{cite web
{{cite web
Line 10: Line 12:


==Function==
==Function==
 
[[Mutation]]s in this gene cause the [[X-linked syndrome|X-linked]] [[Kallmann syndrome|Kallmann Syndrome]]. The encoded [[protein]] is similar in sequence to proteins known to function in [[Neural cell adhesion molecule|neural cell adhesion]] and [[axon]]al migration. In addition, this [[cell (biology)|cell]] surface protein is [[N-glycosylation|N-glycosylated]], and may have [[antiprotease]] activity. [provided by RefSeq, Jul 2008].
Mutations in this gene cause the X-linked Kallmann syndrome. The encoded protein is similar in sequence to proteins known to function in neural cell adhesion and axonal migration. In addition, this cell surface protein is N-glycosylated and may have anti-protease activity. [provided by RefSeq, Jul 2008].


== References ==
== References ==
{{reflist}}
{{reflist}}


== Further reading ==
== Further reading ==
{{refbegin | 2}}
{{refbegin | 2}}
*{{cite journal |vauthors=Söderlund D, Canto P, Méndez JP |title=Identification of three novel mutations in the KAL1 gene in patients with Kallmann syndrome |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=6 |pages=2589–92 |date=June 2002 |pmid=12050219 |doi=10.1210/jcem.87.6.8611 |url=}}
*{{cite journal |vauthors=Söderlund D, Canto P, Méndez JP |title=Identification of three novel mutations in the KAL1 gene in patients with Kallmann syndrome |journal=Journal of Clinical Endocrinology]] Metab. |volume=87 |issue=6 |pages=2589–92 |date=June 2002 |pmid=12050219 |doi=10.1210/jcem.87.6.8611 |url=}}
*{{cite journal |vauthors=Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, Pêcheux C, Le Tessier D, Cruaud C, Delpech M, Speleman F, Vermeulen S, Amalfitano A, Bachelot Y, Bouchard P, Cabrol S, Carel JC, Delemarre-van de Waal H, Goulet-Salmon B, Kottler ML, Richard O, Sanchez-Franco F, Saura R, Young J, Petit C, Hardelin JP |title=Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome |journal=Nat. Genet. |volume=33 |issue=4 |pages=463–5 |date=April 2003 |pmid=12627230 |doi=10.1038/ng1122 |url=}}
*{{cite journal |vauthors=Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, Pêcheux C, Le Tessier D, Cruaud C, Delpech M, Speleman F, Vermeulen S, Amalfitano A, Bachelot Y, Bouchard P, Cabrol S, Carel JC, Delemarre-van de Waal H, Goulet-Salmon B, Kottler ML, Richard O, Sanchez-Franco F, Saura R, Young J, Petit C, Hardelin JP |title=Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome |journal=[[Nat. Genet|Nat. Genet.]] |volume=33 |issue=4 |pages=463–5 |date=April 2003 |pmid=12627230 |doi=10.1038/ng1122 |url=}}
*{{cite journal |vauthors=Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, Kawakita S, Minowada S, Shimotsuka A, Shishiba Y, Yokozawa M, Yasuda T, Nagasaki K, Hasegawa D, Hasegawa Y, Tachibana K, Naiki Y, Horikawa R, Tanaka T, Ogata T |title=Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=3 |pages=1079–88 |date=March 2004 |pmid=15001591 |doi=10.1210/jc.2003-030476 |url=}}
*{{cite journal |vauthors=Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, Kawakita S, Minowada S, Shimotsuka A, Shishiba Y, Yokozawa M, Yasuda T, Nagasaki K, Hasegawa D, Hasegawa Y, Tachibana K, Naiki Y, Horikawa R, Tanaka T, Ogata T |title=Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=3 |pages=1079–88 |date=March 2004 |pmid=15001591 |doi=10.1210/jc.2003-030476 |url=}}
*{{cite journal |vauthors=Lee SH, Han JH, Cho SW, Lee WH, Cha KY, Lee MH |title=Mutation analysis of the KAL gene in female patients with gonadotropin-releasing hormone deficiency |journal=Yonsei Med. J. |volume=45 |issue=1 |pages=107–12 |date=February 2004 |pmid=15004876 |doi=10.3349/ymj.2004.45.1.107 |url=}}
*{{cite journal |vauthors=Lee SH, Han JH, Cho SW, Lee WH, Cha KY, Lee MH |title=Mutation analysis of the KAL gene in female patients with gonadotropin-releasing hormone deficiency |journal=[[Yonsei Med. J.]] |volume=45 |issue=1 |pages=107–12 |date=February 2004 |pmid=15004876 |doi=10.3349/ymj.2004.45.1.107 |url=}}
*{{cite journal |vauthors=Hu Y, González-Martínez D, Kim SH, Bouloux PM |title=Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator |journal=Biochem. J. |volume=384 |issue=Pt 3 |pages=495–505 |date=December 2004 |pmid=15324302 |pmc=1134135 |doi=10.1042/BJ20041078 |url=}}
*{{cite journal |vauthors=Hu Y, González-Martínez D, Kim SH, Bouloux PM |title=Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator |journal=[[Biochem. J.]] |volume=384 |issue=Pt 3 |pages=495–505 |date=December 2004 |pmid=15324302 |pmc=1134135 |doi=10.1042/BJ20041078 |url=}}
*{{cite journal |vauthors=Cariboni A, Pimpinelli F, Colamarino S, Zaninetti R, Piccolella M, Rumio C, Piva F, Rugarli EI, Maggi R |title=The product of X-linked Kallmann's syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons |journal=Hum. Mol. Genet. |volume=13 |issue=22 |pages=2781–91 |date=November 2004 |pmid=15471890 |doi=10.1093/hmg/ddh309 |url=}}
*{{cite journal |vauthors=Cariboni A, Pimpinelli F, Colamarino S, Zaninetti R, Piccolella M, Rumio C, Piva F, Rugarli EI, Maggi R |title=The product of X-linked Kallmann's syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons |journal=[[Hum. Mol. Genet.]] |volume=13 |issue=22 |pages=2781–91 |date=November 2004 |pmid=15471890 |doi=10.1093/hmg/ddh309 |url=}}
*{{cite journal |vauthors=González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, Vannelli GB, Turnbull J, Bouloux PM |title=Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism |journal=J. Neurosci. |volume=24 |issue=46 |pages=10384–92 |date=November 2004 |pmid=15548653 |doi=10.1523/JNEUROSCI.3400-04.2004 |url=}}
*{{cite journal |vauthors=González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, Vannelli GB, Turnbull J, Bouloux PM |title=Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism |journal=[[J. Neurosci.]] |volume=24 |issue=46 |pages=10384–92 |date=November 2004 |pmid=15548653 |doi=10.1523/JNEUROSCI.3400-04.2004 |url=}}
*{{cite journal |vauthors=Söderlund D, Vilchis F, Méndez JP |title=Polymorphic changes in the KAL1 gene: not all of them should be classified as polymorphisms |journal=J. Endocrinol. Invest. |volume=27 |issue=8 |pages=765–9 |date=September 2004 |pmid=15636431 |doi=10.1007/BF03347520 |url=}}
*{{cite journal |vauthors=Söderlund D, Vilchis F, Méndez JP |title=Polymorphic changes in the KAL1 gene: not all of them should be classified as polymorphisms |journal=J. Endocrinol. Invest. |volume=27 |issue=8 |pages=765–9 |date=September 2004 |pmid=15636431 |doi=10.1007/BF03347520 |url=}}
*{{cite journal |vauthors=Hu Y, Sun Z, Eaton JT, Bouloux PM, Perkins SJ |title=Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling |journal=J. Mol. Biol. |volume=350 |issue=3 |pages=553–70 |date=July 2005 |pmid=15949815 |doi=10.1016/j.jmb.2005.04.031 |url=}}
*{{cite journal |vauthors=Hu Y, Sun Z, Eaton JT, Bouloux PM, Perkins SJ |title=Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling |journal=J. Mol. Biol. |volume=350 |issue=3 |pages=553–70 |date=July 2005 |pmid=15949815 |doi=10.1016/j.jmb.2005.04.031 |url=}}


{{refend}}
{{refend}}
{{NLM content}}




{{gene-X-stub}}
{{gene-X-stub}}
{{NLM content}}

Latest revision as of 07:06, 15 January 2019

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Anosmin 1 is a protein that in humans is encoded by the ANOS1 gene. [1]

Function

Mutations in this gene cause the X-linked Kallmann Syndrome. The encoded protein is similar in sequence to proteins known to function in neural cell adhesion and axonal migration. In addition, this cell surface protein is N-glycosylated, and may have antiprotease activity. [provided by RefSeq, Jul 2008].

References

  1. ↑ "Entrez Gene: Anosmin 1". Retrieved 2018-08-18.

Further reading

  • Söderlund D, Canto P, Méndez JP (June 2002). "Identification of three novel mutations in the KAL1 gene in patients with Kallmann syndrome". Journal of Clinical Endocrinology]] Metab. 87 (6): 2589–92. doi:10.1210/jcem.87.6.8611. PMID 12050219.
  • Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, Pêcheux C, Le Tessier D, Cruaud C, Delpech M, Speleman F, Vermeulen S, Amalfitano A, Bachelot Y, Bouchard P, Cabrol S, Carel JC, Delemarre-van de Waal H, Goulet-Salmon B, Kottler ML, Richard O, Sanchez-Franco F, Saura R, Young J, Petit C, Hardelin JP (April 2003). "Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome". Nat. Genet. 33 (4): 463–5. doi:10.1038/ng1122. PMID 12627230.
  • Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, Kawakita S, Minowada S, Shimotsuka A, Shishiba Y, Yokozawa M, Yasuda T, Nagasaki K, Hasegawa D, Hasegawa Y, Tachibana K, Naiki Y, Horikawa R, Tanaka T, Ogata T (March 2004). "Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients". J. Clin. Endocrinol. Metab. 89 (3): 1079–88. doi:10.1210/jc.2003-030476. PMID 15001591.
  • Lee SH, Han JH, Cho SW, Lee WH, Cha KY, Lee MH (February 2004). "Mutation analysis of the KAL gene in female patients with gonadotropin-releasing hormone deficiency". Yonsei Med. J. 45 (1): 107–12. doi:10.3349/ymj.2004.45.1.107. PMID 15004876.
  • Hu Y, González-Martínez D, Kim SH, Bouloux PM (December 2004). "Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator". Biochem. J. 384 (Pt 3): 495–505. doi:10.1042/BJ20041078. PMC 1134135. PMID 15324302.
  • Cariboni A, Pimpinelli F, Colamarino S, Zaninetti R, Piccolella M, Rumio C, Piva F, Rugarli EI, Maggi R (November 2004). "The product of X-linked Kallmann's syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons". Hum. Mol. Genet. 13 (22): 2781–91. doi:10.1093/hmg/ddh309. PMID 15471890.
  • González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, Vannelli GB, Turnbull J, Bouloux PM (November 2004). "Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism". J. Neurosci. 24 (46): 10384–92. doi:10.1523/JNEUROSCI.3400-04.2004. PMID 15548653.
  • Söderlund D, Vilchis F, Méndez JP (September 2004). "Polymorphic changes in the KAL1 gene: not all of them should be classified as polymorphisms". J. Endocrinol. Invest. 27 (8): 765–9. doi:10.1007/BF03347520. PMID 15636431.
  • Hu Y, Sun Z, Eaton JT, Bouloux PM, Perkins SJ (July 2005). "Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling". J. Mol. Biol. 350 (3): 553–70. doi:10.1016/j.jmb.2005.04.031. PMID 15949815.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


Retrieved from "https://www.wikidoc.org/index.php?title=ANOS1&oldid=1542139"